Not Medicare Enrolled

Dr. Roy Fleischmann, M.D.

Optician · Dallas, TX
Consulting-driven
8144 WALNUT HILL LN, Dallas, TX 75231
2145400700
In practice since 2005 (20 years)
NPI: 1467451146 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Fleischmann from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fleischmann? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Fleischmann

Dr. Roy Fleischmann is an optician in Dallas, TX, with 20 years in practice.

Between the years covered by Open Payments, Dr. Fleischmann received a total of $1,146,585 from 31 pharmaceutical and/or device companies across 1055 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Fleischmann is Moderate — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice$ $1,146,585 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$1,146,585
Total received (2018-2024)
Avg $163,798/year across 7 years
Top 0% in TX for optician
31
Companies
1,055
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$795,170 (69.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$350,816 (30.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$600 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$80,953
2023
$97,528
2022
$150,610
2021
$166,454
2020
$143,758
2019
$293,003
2018
$214,280

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$284,394
AbbVie, Inc.
$198,312
AbbVie Inc.
$163,911
ABBVIE INC.
$136,427
Eli Lilly and Company
$76,513
GlaxoSmithKline, LLC.
$75,724
E.R. Squibb & Sons, L.L.C.
$43,491
Lilly USA, LLC
$28,638
Novartis Pharmaceuticals Corporation
$19,322
Janssen Scientific Affairs, LLC
$18,266
NOVARTIS PHARMACEUTICALS CORPORATION
$16,027
Boehringer Ingelheim Pharmaceuticals, Inc.
$14,190
Gilead Sciences, Inc.
$13,506
EMD Serono, Inc.
$9,600
WHITEHALL INTERNATIONAL INC
$8,500
Amgen Inc.
$8,117
UCB SA
$6,351
PFIZER CHILE S.A.
$6,300
Mallinckrodt LLC
$4,375
GENZYME CORPORATION
$4,255
Mylan Inc.
$1,953
Celltrion, Inc.
$1,650
Almirall LLC
$1,600
Genentech USA, Inc.
$1,558
Samsung Bioepis Co., Ltd.
$1,400
Sandoz Inc.
$649
Celltrion Healthcare Co., Ltd
$600
Assertio Therapeutics, Inc.
$475
PFIZER INTERNATIONAL LLC
$370
AstraZeneca Pharmaceuticals LP
$62
Aurinia Pharma U.S., Inc.
$50
Top 3 companies account for 56.4% of total payments
Associated products mentioned in payments ›
ABRILADA · ACTHAR · COSENTYX · Enbrel · HUMIRA · Humira · KEVZARA · LUPKYNIS · ORENCIA · OTREXUP · Otezla · RENFLEXIS · RETACRIT · RINVOQ · Rinvoq · Rituxan · SKYRIZI · TALTZ · TREMFYA · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (69%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 0% for optician in TX.

Looking for a optician in Dallas?
Compare opticians in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse opticians nearby

Geographic Context

Opticians within 10 mi
504
Per 100K population
19.4
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Fleischmann is a optician, and high industry engagement (consulting-driven, top 0%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Fleischmann receive payments from pharmaceutical companies?
Yes. Dr. Fleischmann received a total of $1,146,585 from 31 companies across 1,055 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Fleischmann) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →